PEPG PepGen Inc.
USHealthcareAs of 2026-07-09 16:00
Why PEPG matters now
PepGen Inc. (PEPG) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.30 with +15.87% on the session and $159.1M in market capitalization; recent performance reads 1-month +29.71% and YTD -72.50%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-17.8M, and EPS of $-0.42. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -62.4%.
The latest indexable market news headline is "PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.50; recent insider activity includes Kasraian Kasra filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.92
P/S
0.00
EV/EBITDA
-1.29
DCF Value
$1.01
FCF Yield
-62.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-59.9%
ROA
-49.4%
ROIC
-54.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-17.8M | $-0.42 |
| Q4 2025 | $0.00 | $-18.3M | $-0.43 |
| FY 2025 | $0.00 | $-89.7M | $-2.12 |
| Q3 2025 | $0.00 | $-18.0M | $-0.55 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.50
Target (Median)
$5.50
Target Range
$4.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.93
PepGen Inc. is a clinical-stage biopharmaceutical company specializing in the development of oligonucleotide therapeutics designed to treat severe neuromuscular and neurological disorders. Its most advanced candidate, PGN-EDO51 – an EDO peptide – is currently undergoing Phase 1 clinical trials for individuals suffering from Duchenne muscular dystrophy (DMD). The company's pipeline also includes PGN-EDODM1, an EDO peptide-conjugated PMO aimed at myotonic dystrophy type 1, alongside other EDO therapeutic candidates for DMD, specifically PGN-EDO53, PGN-EDO45, and PGN-EDO44. Established in 2018, PepGen Inc. operates from its headquarters in Cambridge, Massachusetts.